Dataset Information


Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

ABSTRACT: Acquired resistance to BRAF inhibitors often involves MAPK re-activation, yet the MEK inhibitor trametinib showed minimal clinical activity in melanoma patients that had progressed on BRAF-inhibitor therapy. Selective ERK inhibitors have been proposed as alternative salvage therapies. We show that ERK inhibition is more potent than MEK inhibition at suppressing MAPK activity and inhibiting the proliferation of multiple BRAF inhibitor resistant melanoma cell models. Nevertheless, melanoma cells often failed to undergo apoptosis in response to ERK inhibition, because the relief of ERK-dependent negative feedback activated RAS and PI3K signalling. Consequently, the combination of ERK and PI3K/mTOR inhibition was effective at promoting cell death in all resistant melanoma cell models, and was substantially more potent than the MEK/PI3K/mTOR inhibitor combination. Our data indicate that a broader targeting strategy concurrently inhibiting ERK, rather than MEK, and PI3K/mTOR may circumvent BRAF inhibitor resistance, and should be considered during the clinical development of ERK inhibitors.


PROVIDER: S-EPMC5528644 | BioStudies | 2014-01-01


REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC4826182 | BioStudies
2016-01-01 | S-EPMC5215252 | BioStudies
2013-01-01 | S-EPMC3956616 | BioStudies
1000-01-01 | S-EPMC3593920 | BioStudies
2013-01-01 | S-EPMC3701070 | BioStudies
2011-01-01 | S-EPMC3237573 | BioStudies
2014-01-01 | S-EPMC4300142 | BioStudies
1000-01-01 | S-EPMC3326670 | BioStudies
2017-01-01 | S-EPMC5628883 | BioStudies
1000-01-01 | S-EPMC5216972 | BioStudies